Medeor Life Care LLP

Medeor Life Care LLP is a pharmaceutical enterprise established on June 29, 2015, in Gurgaon, Haryana, India. Founded by two experienced pharmaceutical specialists, the company aims to serve the international pharmaceutical industry by providing guidance in establishing pharmaceutical businesses across various countries and exporting quality finished formulations.

The company operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAE-2733. As of March 31, 2024, Medeor Life Care LLP reported a total obligation of contribution of ₹1.50 crore. The firm's registered office is located at J-172, Cedar Crest Nirvana Country, Sector-50, Gurgaon, Haryana, 122003, India.

Medeor Life Care LLP specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans various therapeutic categories, such as gastrointestinal, cardiovascular, anti-diabetics, pain management, antibiotics, and respiratory treatments.

Medeor Life Care LLP collaborates with high-quality manufacturing units in India and abroad to supply a diverse range of finished pharmaceutical formulations. These formulations include oral solid dosage forms (tablets and capsules), suppositories, pessaries, liquids in the form of syrups and suspensions, and injectables such as infusions (LVP and SVP) and dry powder injections.

The leadership team of Medeor Life Care LLP comprises:

• Swati Nagpal: Designated Partner
• Rajiv Bedi: Designated Partner
• Poonam Gupta: Designated Partner

These individuals play pivotal roles in steering the company's strategic direction and operations.

Medeor Life Care LLP's export activities are primarily focused on markets in Africa, Latin America, and Southeast Asia. The company's trade data indicates shipments to countries such as Burundi, Myanmar, and Azerbaijan. While specific regulatory approvals in the US, EU, UK, Australia, and Japan are not detailed in the available sources, the company's established presence in various international markets suggests compliance with relevant regulatory standards.

Medeor Life Care LLP has made significant inroads into emerging markets, particularly in Africa and Southeast Asia. The company's export data highlights shipments to countries like Burundi, Myanmar, and Azerbaijan. These markets often require adherence to specific regulatory standards, such as WHO prequalification, to ensure product quality and safety. While the company's certifications are not explicitly detailed in the available sources, its active engagement in these regions suggests a commitment to meeting international regulatory requirements.

Medeor Life Care LLP's export strategy demonstrates a focused approach, with a significant concentration on the Diabetes & Endocrine therapeutic category, accounting for 94.3% of its total export value. This specialization indicates a strategic emphasis on addressing the global demand for anti-diabetic medications. The company's portfolio concentration, with its top five products comprising 100% of its exports, suggests a targeted product strategy aimed at maximizing impact within its chosen therapeutic area.

Specific details regarding Medeor Life Care LLP's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not available in the provided sources. This lack of information may indicate that the company does not currently export to the U.S. market or has not pursued FDA approvals for its products.

The available information does not specify whether Medeor Life Care LLP holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. These certifications are crucial for accessing certain international markets and ensuring product quality. The company's active engagement in various global markets suggests a potential commitment to obtaining such certifications, but explicit confirmation is lacking.

Medeor Life Care LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, approvals from state drug controllers, and export No Objection Certificates (NOCs) are not detailed in the available sources. However, the company's established presence in the pharmaceutical export sector implies compliance with Indian regulatory requirements.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Medeor Life Care LLP. This absence suggests that the company maintains a clean regulatory record, reflecting adherence to industry standards and regulations.

In the therapeutic category of anti-diabetics, Medeor Life Care LLP faces competition from several established pharmaceutical companies. While specific market share data is not available, the company's focus on this segment positions it among key players in the global anti-diabetic market. The company's export data indicates shipments to countries such as Burundi, Myanmar, and Azerbaijan, suggesting a competitive presence in emerging markets.

Medeor Life Care LLP's key differentiators include its specialized focus on the anti-diabetic segment, which constitutes the majority of its export value. The company's ability to establish strong ties with high-quality manufacturing units in India and abroad enables it to offer a diverse range of finished pharmaceutical formulations. Additionally, its experience in turning around non-profitable operations into profit-oriented entities demonstrates a robust operational strategy.

Medeor Life Care LLP's current strategic direction centers on the export of finished pharmaceutical formulations, with a particular emphasis on anti-diabetic products. The company's active engagement in various international markets, including emerging regions, reflects a strategy aimed at global expansion. Future outlooks would benefit from the company's potential pursuit of international certifications and regulatory approvals to enhance its market presence.

Medeor Life Care LLP has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $3.9 million USD and 82 shipments recorded between 2022 and 2026. The company's portfolio concentration, with its top five products comprising 100% of its exports, indicates a focused and reliable supply chain. The absence of publicly available records of regulatory issues further underscores the company's reliability as a supplier.

Importers should verify the following certifications when considering products from Medeor Life Care LLP:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
• WHO Prequalification: Verify if the company's products are prequalified by the World Health Organization.
• EU GMP Certification: Check for compliance with European Union Good Manufacturing Practice standards.
• ISO Certification: Ensure the company holds relevant International Organization for Standardization certifications.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.

When conducting due diligence on Medeor Life Care LLP, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's adherence to relevant regulatory standards in target markets.
• Assess Financial Stability: Review the company's financial statements and credit history.
• Evaluate Product Quality: Request samples and assess product quality against industry standards.
• Check References: Obtain feedback from other clients or partners who have worked with the company.

Be cautious of red flags such as inconsistent product quality, lack of transparency in operations, or unresolved regulatory issues. Pre-order checks should include verifying certifications, assessing supply chain reliability, and ensuring clear communication channels.